After being fired, I became the light of medicine

Chapter 113: The Phase II Clinical Trial of Hepatocyte Activator has ended! (Additional update for the Annual Ring Empire!)
Zhang Yang looked over, and within two seconds, his expression suddenly became a little strange.

How could he not know this "LivClearX"... This is the lowest 50% version of the "liver cell activator"!

He said calmly with a stern face:

"what happened?"

"Nothing!"

"Although this drug is mainly promoted as a treatment for fatty liver, one of its therapeutic effects is 'preventing the progression of liver cirrhosis', so several of our patients who did not participate in the trial want to buy it and try it."

"I was thinking that if you know about this drug, you could tell me about it. If a patient asks about it later, I can give some advice."

"I think the Novartis drug is about to finish Phase III clinical trials. It will probably be available in the market in less than two months. Several patients are even looking for someone to buy it in the United States..."

Zhang Yang was slightly stunned when he heard this, but he still understood these patients and their families.

Firstly, the "hepatocyte activator" had not been effective before and there were few clinical spots available, so it was normal for patients to be anxious.

Secondly, if someone’s elder or child is really sick, it is human nature for everyone to want to buy and try the good medicine when they hear that there is one.

but.

At this moment, he really wanted to laugh but didn't dare to.

Our drug, which has a 70% efficacy, is already in Phase II clinical trials. After two or three more revisions, it will reach 100% efficacy in Phase III clinical trials.

Instead of having high hopes for their own medicine, they go out of their way to buy the younger version of the "hepatocyte activator"... Isn't this just exporting and selling it domestically?
Fortunately, 50% of "LivClearX" has some effect, at least it can stabilize liver cirrhosis and prevent it from getting worse.

The most important thing is that this is our own product anyway, we can’t persuade others not to buy it…

"Hey, Director Chen, please give me some advice. Our 'liver cell activator' is definitely more effective than this."

"But those who can buy on behalf of others are not ordinary people. If they really want to buy, don't stop them. This medicine is still somewhat effective."

Chen Wen was stunned for a moment, then nodded.

"Okay, then I'll do as you say!"

……

The news that the "liver cell regeneration activator" finally showed its effect after long-term use excited the entire Qingshan Pharmaceutical R&D team.

Zhang Yang also basically understood the treatment cycle and therapeutic effect of this drug on human liver cirrhosis.

On November 11, under the guidance of Zhang Yang, the effective activator component of the "hepatocyte activator" was further improved, and the therapeutic effect was increased from 7% to 70%.

12 month 7 day,
The three-month Phase II clinical trial of the "hepatocyte activator" has ended, and all patients received comprehensive clinical data for the first time.

A total of 94 people were recruited in this Phase II clinical trial, of which 54 were in the experimental group and 40 were in the control group.

Among the 54-person trial group, only three patients had a poor response to the activator effect, and the drug effective response rate reached 94.4%.

The results of transaminase, alpha-fetoprotein, liver biopsy and B-ultrasound of the other 51 people who responded all improved, among which the transaminase, alpha-fetoprotein and bilirubin indicators returned to normal.

Imaging B-ultrasound, liver biopsy, and CT scans have shown slight improvement, but still need to be observed.

The 40 people in the control group showed no significant changes in their indicators compared to three months ago, and three of them even developed ascites and gastrointestinal bleeding during hospitalization.

The obviously different clinical results quickly spread among patients. Now everyone can see that after taking Qingshan Pharmaceutical's "Hepatocyte Activator" for three months, it actually worked for cirrhosis!
The news that the “liver activator” was effective immediately spread to major liver cirrhosis patient groups, inspiring countless patients!
Suddenly, heated discussions broke out among the patients!
"Old Wang, are you telling the truth? Can Qingshan Pharmaceutical's new drug really reverse liver cirrhosis?"

"That's not the case, but I know that every patient who entered the trial group had their alpha-fetoprotein, transaminase, and bilirubin levels reduced, and in the past three months, no one developed ascites or internal bleeding!"

"Holy crap! I know that several patients with advanced liver cirrhosis participated in the trial? When they joined the group, I saw that they were almost dying, but they are fine? They didn't even develop ascites?!"

"How can I lie to you? Why don't you come to the hospital and see it yourself? Everyone is clamoring to participate in the Phase III clinical trial!" The evaluation of the subjects is relatively subjective.
Three days later, Tsingshan Pharmaceutical released all the statistical data of the Phase II clinical trial to the clinical trial data of the State Food and Drug Administration. All pharmaceutical companies and individuals can view the public clinical data!
At the same time that Zhang Yang announced the data, on the other side of the ocean, "LivClearX" represented by Novartis also completed the Phase III clinical trial.

LivClearX's Phase III clinical data for fatty liver disease remains excellent, and praise and expectations for this fatty liver drug are growing louder on Twitter and Titok.

but.

Novartis was not happy with the praise on the Internet. Gradually, even President Green felt that public opinion seemed to be going astray.

In the office, President Green sat on a large, soft leather sofa. Opposite the coffee table sat two vice presidents, Klein and Friedman.

Friedman is in charge of marketing and sales, and this time he is also fully responsible for the promotion and publicity of the new drug in "LivClearX".

Green put down the coffee cup in his hand and frowned.

"Friedman, I'm sure you've seen a lot of comments about our new drug 'LivClearX' on the Internet. Now both netizens and the media are assuming that 'LivClearX' was developed by us. I feel this is very bad."

"Now that we have passed Phase III clinical trials and are about to be marketed, I think we should come forward to clarify this matter."

Green's gaze made it impossible for Friedman to avoid it.

He noticed this matter three months ago, but it is obvious that online public opinion is very effective in promoting Novartis and "LivClearX".

He had delayed for three months, but now there was no way to delay it any longer.

"Mr. President, I agree with you."

"But I think the public opinion on the Internet is very helpful to us, and we have never publicly advertised that 'LivClearX' was developed by us. Such an impression is just created by the media and netizens themselves."

"Besides, any pharmaceutical company that represents a drug will not actively promote the name of its partner. For example, Johnson & Johnson will tell consumers that its popular asthma drug Mepuran comes from Japan's Otsuka Pharmaceutical."

"There is nothing wrong with what we did, so there is no need for us to clarify."

Green was very determined and shook his head:
“Friedman, I understand your emphasis on LivClearX, but Japan is different!”

"This drug comes from China. As you know, the FDA filings show information about Qingshan Pharmaceutical. Once it is published online by other pharmaceutical companies, it will undoubtedly have a very negative impact on us."

"So, we must clarify this matter as soon as possible and not let it continue to ferment."

Friedman stared at Green for several seconds, but eventually succumbed.

There was a flash of disappointment in his eyes:
"Okay, President, I'll follow your instructions, but I hope to take it easy!"

"Our 'LivClearX' is about to be launched. We can wait until everyone has used it and experienced its effects before making it public. This way, we can minimize the company's losses. What do you think?"

Green originally wanted to refuse, but after seeing Friedman's eyes, he hesitated for a few seconds and nodded.

"Okay, let's do as you say."

As he spoke, Green picked up his coffee cup again and took a sip. He did not end the conversation, but changed the subject.

"Okay, now we need to focus on the price of 'LivClearX'!"

"One is the selling price in our market, and the other is the purchase price we give to Tsingshan Pharmaceutical."

"We had only signed a priority agency contract with them before, but now that the Phase III clinical trial has been approved, it's time to talk about this."

"Friedman, tell me what you think!"

……

ps: Today I will update the first chapter, and there are 2 more chapters left for reward.
(End of this chapter)